Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, announces that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market. “We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis’ differentiated late-stage portfolio and develop transformative therapies for patients,” said Martin Babler, President, CEO and Chairman of Alumis.
Read the full article: Alumis Completes Merger with ACELYRIN //
Source: https://www.globenewswire.com/news-release/2025/05/21/3085818/0/en/Alumis-Completes-Merger-with-ACELYRIN.html